ESH Video


September 09, 2022

3rd How to Diagnose and Treat



November 04-06, 2022

Paris, France



The Conference has been reviewed and approved
for CME-CPD accreditation by EBAH. 

The EBAH has approved this educational activity
for 19 CME-CPD credits!

One more reason to register!
The Conference starts in less than two months!


About the Conference:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management. They are based on the presentation and analysis of real clinical cases. Voting technology is used as a self-evaluation tool and to increase scientific interaction.

This How to Diagnose and Treat conference will bring together biologists and clinicians with an interest in Lymphoma in order to explore the most recent advances in the understanding of the pathogenesis and clinical behaviour of the disease.

New data will be presented and spirited debates on how to best apply these insights to the future of Lymphoma therapy are expected

Conference scientific topics:
• Hodgkin’s Lymphoma
• T-cell Lymphoma
• Follicular Lymphoma 
• Aggressive B-Cell Lymphomas 
• Large B-Cell Lymphoma, Practical Management 
• Uncommon Lymphomas— Waldenstrom’s Macroglobulinemia,
Marginal zone lymphoma, Mantle cell lymphoma

Learning objectives:
• Understand recent advances in elucidating the pathogenesis of lymphoma
• Describe recent data on therapeutic regimens for lymphoma
• Understand emerging data on mechanisms of resistance to targeted agents in lymphoma
• Understand the debate about how best to optimize lymphoma therapy in the future

The programme will include:
Plenary Sessions - Interactive Case Presentations
Roundtables - Panel Discussions - Debates
Meet the Expert Sessions - Poster Walks - Voting technology

To meet the faculty, click here!

For more information, click here!


With the support of*:

Major Conference Partners

Level 1 Conference Partners

Supporting Conference Partner

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.